The Technical Analyst
IMAC Holdings, Inc. [IMAC]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Medical - Care Facilities
IMAC Holdings, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.00% $1.010
/ 8 aug 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 33.08 mill |
| EPS: | -0.445 |
| P/E: | -2.27 |
| Earnings Date: | Aug 15, 2022 |
| SharesOutstanding: | 32.75 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2023-02-24 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.27 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -2.27 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.930 - 1.090 ( +/- 7.92%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-21 | Gardzina Sheri | Sell | 9 375 | Time-Based Restricted Stock Unit |
| 2022-05-21 | Ervin Jeffrey S | Buy | 37 500 | Common Stock |
| 2022-02-21 | Lerner Benjamin S | Buy | 100 000 | Common Stock |
| 2022-02-21 | Lerner Benjamin S | Buy | 50 000 | Stock Options |
| 2022-02-21 | Lerner Benjamin S | Buy | 0 |
| INSIDER POWER |
|---|
| 60.00 |
| Last 93 transactions |
| Buy: 1 967 990 | Sell: 886 160 |
Forecast:
01:40 - $0.963
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.010 (2.00% ) |
| Volume | 0.0815 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IMAC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IMAC
IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.
Latest Press Releases
2021-05-26 06:01:00 - Press Release
Imac Holdings To Present At The Summer Solstice - Best Ideas From The Buy Side Conference On Tuesday, June 1, 2021
Brentwood, tenn, may 26, 2021 (globe newswire) -- imac holdin gs, inc. (nasdaq: imac, imacw), a provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announced today that management has been invited to present at the summer solstice - best ideas from the buy side conference, which is being held virtually on june 1 – june 4, 2021.
2021-03-23 17:50:00 - Press Release
Imac Holdings Announces Pricing Of Its Public Offering Of Common Stock
Brentwood, tenn, march 23, 2021 (globe newswire) -- imac holdings, inc. (the “company” or “imac”) (nasdaq: imac, imacw), a provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announced today the pricing of its underwritten registered public offering of 10,625,000 shares of its common stock at a public offering price of $1.60 per share, for total gross proceeds of $17.0 million. the net proceeds, after underwriting discounts, but before estimated expenses of the offering payable by imac, are expected to be approximately $16.0 million. all shares of common stock to be sold in the offering will be sold by the company, except that the company, together with its co-founder and chief operating officer as a selling stockholder, will grant the underwriter for the offering a 45-day option to purchase up to 15% of the shares of common stock in the offering...
2021-03-04 09:00:00 - Press Release
Imac Holdings Reports 2020 Financial Results And Corporate Update
Brentwood, tenn., march 04, 2021 (globe newswire) -- imac holdings, inc. (nasdaq: imac) (“imac” or the “company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced financial results for the year ended december 31, 2020.
2021-03-01 09:25:00 - Press Release
Imac Holdings, Inc. Announces Completion Of First Cohort Of Its Phase 1 Clinical Study Of Umbilical Cord-derived Mesenchymal Stem Cells For The Treatment Of Bradykinesia Due To Parkinson's Disease
Brentwood, tenn, march 01, 2021 (globe newswire) -- imac holdings, inc. (nasdaq: imac) (“imac” or “the company”), today announces it has completed the first cohort of its phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to parkinson's disease.
2021-02-18 09:00:00 - Press Release
Imac Holdings Adds Regenerative Wound Care Service In Regeneration Centers
Insurance to reimburse services providing cell-based amniotic-infused mesh application to chronic non-healing wounds and diabetic foot ulcers
Latest News
2022-05-19 11:04:04 - PennyStocks
Best Penny Stocks To Buy? Einhorn, Lynch, Cohen & Dalio Own These 5
2022-05-19 09:59:40 - InvestorPlace
Legendary Investor Peter Lynch Just Bet on IMAC Stock. 9 Things to Know.
IMAC stock is soaring higher today on news that legendary investor Peter Lynch has taken a stake in little-known IMAC Holdings. The post Legendary Investor Peter Lynch Just Bet on IMAC Stock.
2022-04-07 14:32:28 - InvestorPlace
Time to Take Profits on IMAC Stock After Shares Soar on Walmart News
It is time to sell your IMAC stock and make a nice profit on the recent rally because the company hasn't shown the ability to make profits. The post Time to Take Profits on IMAC Stock After Shares Soar on Walmart News appeared first on InvestorPlace.
2022-01-07 16:07:35 - PennyStocks
Best Reddit Penny Stocks To Buy Now? 5 Trending Stocks To Watch Today
What are the best penny stocks to buy today? The post Best Reddit Penny Stocks To Buy Now?
2021-08-06 16:04:33 - Zacks Investment Research
Will IMAC Holdings, Inc. (IMAC) Report Negative Q2 Earnings? What You Should Know
IMAC Holdings, Inc. (IMAC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2021-05-26 06:01:00 - GlobeNewsWire
IMAC Holdings to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on Tuesday, June 1, 2021
Brentwood, Tenn, May 26, 2021 (GLOBE NEWSWIRE) -- IMAC Holdin gs, Inc. (Nasdaq: IMAC, IMACW), a provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announced today that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021.
2021-03-23 17:50:00 - GlobeNewsWire
IMAC Holdings Announces Pricing of its Public Offering of Common Stock
Brentwood, Tenn, March 23, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (the “Company” or “IMAC”) (Nasdaq: IMAC, IMACW), a provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announced today the pricing of its underwritten registered public offering of 10,625,000 shares of its common stock at a public offering price of $1.60 per share, for total gross proceeds of $17.0 million. The net proceeds, after underwriting discounts, but before estimated expenses of the offering payable by IMAC, are expected to be approximately $16.0 million. All shares of common stock to be sold in the offering will be sold by the Company, except that the Company, together with its co-founder and chief operating officer as a selling stockholder, will grant the underwriter for the offering a 45-day option to purchase up to 15% of the shares of common stock in the offering...
2021-03-04 09:00:00 - GlobeNewsWire
IMAC Holdings Reports 2020 Financial Results and Corporate Update
BRENTWOOD, Tenn., March 04, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced financial results for the year ended December 31, 2020.
2021-03-01 09:25:00 - GlobeNewsWire
IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease
BRENTWOOD, Tenn, March 01, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has completed the first cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease.
2021-02-18 09:00:00 - GlobeNewsWire
IMAC Holdings Adds Regenerative Wound Care Service in Regeneration Centers
Insurance to Reimburse Services Providing Cell-Based Amniotic-Infused Mesh Application to Chronic Non-Healing Wounds and Diabetic Foot Ulcers